TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06626568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline as Placebo (ultrasound-guided subacromial injection)
Description: ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline as Placebo (gluteal muscle inection)
Description: gluteal injection of 5 ml normal saline at week 0,2,4.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home exercise
Description: The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: home exercise
Description: The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
Study: NCT06623526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2402
Description: Test Drug: YHR2402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2402
Description: Test Drug: YHR2402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2402+YHR2403
Description: Test Drug: YHR2402+YHR2403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2402+YHR2403
Description: Test Drug: YHR2402+YHR2403
Study: NCT06628323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Intervention employing Neurofeedback
Description: Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality-based Intervention
Description: Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
Study: NCT06686602

Intervention type: OTHER
Intervention: No drug
Description: This is a non-interventional study and no study drug will be administered.
Study: NCT05953194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to traditional health messages
Description: Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to control (neutral) messages
Description: Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
Study: NCT04878705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-201
Description: a single subcutaneous injection
Study: NCT06698263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group (placebo)
Description: placebo administration
Study: NCT04878705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a single subcutaneous injection
Study: NCT05760794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-barbed delayed absorbable suture
Description: The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbed delayed absorbable suture
Description: The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
Study: NCT05989399

Intervention type: DIAGNOSTIC_TEST
Intervention: circulating neutrophils
Description: evaluation of circulating neutrophils level
Study: NCT06573658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT)
Description: It will be a two-session training with each session lasting for approximately half an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control (control)
Description: It will be a two-session training with each session lasting for approximately half an hour. The same training duration and format will be used as the PBT group, except no perturbations will be induced during the treadmill walking.
Study: NCT06696170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX nano-pFA 360 Endocardial Ablation Catheter System
Description: The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
Study: NCT06700681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: TIVA induction and maintain with Propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: TIVA induction and maintain with Propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: TIVA induction and maintain with Remimazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: TIVA induction and maintain with Remimazolam.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: With intubation and controlled ventilation to maintain airway
Description: Patient receives intubation and controlled ventilation to maintain airway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With intubation and controlled ventilation to maintain airway
Description: Patient receives intubation and controlled ventilation to maintain airway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maintain spontaneous ventilation without intubation
Description: Patient maintains spontaneous ventilation without intubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maintain spontaneous ventilation without intubation
Description: Patient maintains spontaneous ventilation without intubation.
Study: NCT06700525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Sedentary Behavior Habit Formation
Description: Action Plans Addition to the StandUPTV platform:~The StandUPTV mHealth platform will be used to assess SST and deliver behavior change components. Participants will receive a technology kit including a Fitbit Charge 4+ and Wi-Fi-enabled smart plugs. The Fitbit and smart plugs will need to be used for the entire duration of the study participation. Participants will also be assisted with establishing an action plan for a non-sedentary break from evening sedentary screen time, which will be trigger by a StandUPTV alert delivered after performing 30 minutes of evening sedentary screen time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Sedentary Behavior Habit Formation
Description: Action Plans Addition to the StandUPTV platform:~The StandUPTV mHealth platform will be used to assess SST and deliver behavior change components. Participants will receive a technology kit including a Fitbit Charge 4+ and Wi-Fi-enabled smart plugs. The Fitbit and smart plugs will need to be used for the entire duration of the study participation. Participants will also be assisted with establishing an action plan for a non-sedentary break from evening sedentary screen time, which will be trigger by a StandUPTV alert delivered after performing 30 minutes of evening sedentary screen time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Screen Time Reduction Smartphone App
Description: The StandUPTV application is used to monitor and reduce sedentary screen time (SST). The StandUPTV app has three components: LOCKOUT: Electronic lockout turns off screens when a predetermined limit is reached (50% of baseline value of weekly sedentary screen time). The app also includes planning tools and personalized strategies to limit SST. TEXT: Push notification prompts provide reminders, coaching, and personalized feedback (up to 2 per day). EARN: Opportunities to earn SST by engaging in MVPA, measured in 10-minute bouts.
Study: NCT06689917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY231 Injection
Description: Upon enrolment, leukapheresis will be performed and patients will receive 3-5 days of fludarabine and cyclophosphamide lymphodepleting therapy followed by an intravenous infusion of the JY231.
Study: NCT06339827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List
Description: Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
Study: NCT05889559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Ultrafiltration Catheters
Description: patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
Study: NCT00863538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Study: NCT06700772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixing bone marrow aspirate concentrate from maxillary tuberosity with bovine bone
Description: open sinus lifting using bone marrow aspirate concentrate from maxillary tuberosity and mixing it with bovine bone .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mixing autogenous bone with bovine bone
Description: open sinus lifting using autogenous bone from retromolar area mixed with bovine bone
Study: NCT06702293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital psychotherapeutic intervention
Description: Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy365
Description: Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.
Study: NCT06701799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ L-PRF 1 mm
Description: The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ L-PRF 2 mm
Description: The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
Study: NCT06702046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous pulsed radiofrequency acupuncture
Description: For the TCPRF acupuncture group, we choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. Electrical stimulation is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
Study: NCT06532695

Intervention type: OTHER
Intervention: No intervention will be provided.
Description: no intervention will be provided.
Study: NCT06702046

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparison
Description: same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
Study: NCT06702891

Intervention type: OTHER
Intervention: Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing
Description: The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.

Intervention type: OTHER
Intervention: Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing
Description: The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
Study: NCT06702826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab combined with SRS
Description: Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
Study: NCT06702397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microscope
Description: The microscope provides a direct examination of the testicular parenchyma at 20-25x magnification.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical loupes
Description: Surgical loupes offer magnification of 3.5-5x.
Study: NCT06703788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A fiixed combination of Chinese herbal medicine
Description: a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
Study: NCT04777344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Specialist (TTS) intervention
Description: A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
Study: NCT06703788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture could be used based on medication therapy at following acupoints: CV9, ST25, SP15, ST28, ST40, and two auricular points (stomach and hunger points)
Study: NCT06703580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric prilocaine 2% 40 mg
Description: this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric prilocaine 2% 50 mg
Description: comparison of 3 different doses of prilocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric prilocaine 2% 60 mg
Description: this study compare 3 different doses of prilocaine
Study: NCT06702514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin
Description: It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin
Description: It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Description: The balneotherapy group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. The spa treatment will be given in the form of a 20-minute full body bath in the pool in each session. The spa water temperature will be 38-40 degrees Celsius.
Study: NCT06703515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake transnasal laser-assisted surgery (TNLS)
Description: For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microlaryngeal surgery (MLS)
Description: For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
Study: NCT06702709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: The IASTM method will be applied bilaterally to each target muscle, duration 25 minutes. During treatment, three repetitions are performed on each target muscle, with each repetition lasting 50 seconds. The IASTM technique will be applied at a 60-degree angle. The application sequence follows a specific pattern: For the first 10 seconds, light pressure will be applied during the sweeping stroke, and for the next 20 seconds, moderate pressure will apply during the fanning and brushing strokes. Finally, 10 seconds of deep pressure will administer utilizing oblique sweeping strokes. To help the tissues relax, the treatment will finish with mild sweeping and broad strokes on the hamstring region for 10 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The following posture will be repeated 3 times on the bilateral lower limb in one session and maintained for 50 seconds with 60 seconds rest between each posture. The total duration of NDT will be 25 minutes.
Study: NCT06703099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Supplementation
Description: Life Extension® Extend Release Magnesium 250 mg/day of oral magnesium in capsule form to be taken once a day at breakfast/morning over 8 weeks.